R
ReCode Therapeutics
A genetic medicines company developing targeted, disease-modifying therapies for life-limiting respiratory diseases
About ReCode Therapeutics
ReCode Therapeutics is a biotechnology company focused on developing gene therapy solutions for complex respiratory diseases such as cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). The company leverages its deep expertise in drug development and regulatory pathways to advance its lead programs rapidly. ReCode Therapeutics operates in the healthcare and biotechnology market, primarily serving patients with unmet medical needs in respiratory conditions. The business model revolves around research and development (R&D) of novel therapies, followed by clinical trials and eventual commercialization. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company aims to address significant hurdles in targeted delivery and functional restoration for CF and PCD patients, thereby improving their quality of life.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Menlo Park, United States
- Employees
- 59
- Open positions
- None listed
- Dealroom signal
- 62.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Nov 2024 | $15M | — | Cystic Fibrosis Foundation | ↗ |
| SERIES BOther financing | Sep 2023 | $50M | $600M | Osage University Partners · Amgen Ventures · Solasta Ventures · Bioluminescence Ventures | ↗ |
Growth signals
Latest recorded traffic for ReCode Therapeutics is 6K monthly website visits, up 20% over the last three months. ReCode Therapeutics's team declined 23.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cystic Fibrosis Foundation
Series A18 investors entered at this stage
MPM BioImpact
OrbiMed
Colt Ventures
Hunt Technology Ventures
Vida Ventures
Osage University Partners
Sanofi Ventures
EcoR1 Capital- TCTimefolio Capital
- TMTekla Capital Management
- PVPfizer Ventures
Superstring Capital
Matrix Capital Management
Leaps by Bayer
Amgen Ventures- AYAyurMaya
Solasta Ventures
Bioluminescence Ventures
Other known investors1 additional known investor
- TSThe University of Texas Southwestern Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ReCode Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ReCode Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.